Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Kathleen K. Harnden"'
Autor:
Aditya Bardia, Francois-Clement Bidard, Patrick Neven, Guillermo Streich, Alberto J. Montero, Frederic Forget, Marie-Ange Mouret-Reynier, Joo Hyuk Sohn, Donatienne Taylor, Kathleen K. Harnden, Hung Khong, Judit Kocsis, Florence Dalenc, Patrick Dillon, Sunil Babu, Simon Waters, Ines Deleu, Jose Angel García-Sáenz, Emilio Bria, Marina Elena Cazzaniga, Philippe Aftimos, Javier Cortés, Giulia Tonini, Tarek Sahmoud, Nassir Habboubi, Krzysztof Grzegorzewski, Virginia Kaklamani
Publikováno v:
Cancer Research. 83:GS3-01
Background: In patients (pts) with ER+/HER2− metastatic breast cancer (MBC) following progression on prior endocrine and CDK4/6i therapy, the EMERALD trial demonstrated significantly prolonged progression-free survival (PFS) and a manageable safety
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bbaa45271f34c35df8e27971ce271b5c
https://doi.org/10.1158/1538-7445.sabcs22-gs3-01
https://doi.org/10.1158/1538-7445.sabcs22-gs3-01
Autor:
Francois-Clement Bidard, Virginia G. Kaklamani, Patrick Neven, Guillermo Streich, Alberto J. Montero, Frédéric Forget, Marie-Ange Mouret-Reynier, Joo Hyuk Sohn, Donatienne Taylor, Kathleen K. Harnden, Hung Khong, Judit Kocsis, Florence Dalenc, Patrick M. Dillon, Sunil Babu, Simon Waters, Ines Deleu, José A. García Sáenz, Emilio Bria, Marina Cazzaniga, Janice Lu, Philippe Aftimos, Javier Cortés, Shubin Liu, Giulia Tonini, Dirk Laurent, Nassir Habboubi, Maureen G. Conlan, Aditya Bardia
Publikováno v:
Scientia
Journal of Clinical Oncology
Journal of Clinical Oncology, 2022, 40 (28), pp.3246-3256. ⟨10.1200/JCO.22.00338⟩
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, p. JCO2200338 (2022)
Journal of Clinical Oncology
Journal of Clinical Oncology, 2022, 40 (28), pp.3246-3256. ⟨10.1200/JCO.22.00338⟩
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, p. JCO2200338 (2022)
PURPOSE Patients with pretreated estrogen receptor (ER)–positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer have poor prognosis. Elacestrant is a novel, oral selective ER degrader that demonstrated activity in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3250d1e4d1eec1c650e6a9b2f6960b1
https://hdl.handle.net/10281/402049
https://hdl.handle.net/10281/402049
Autor:
Carolina Salvador-Morales, Kathleen K Harnden, Lei Li, Greg Petruncio, Deepanjali Patil, Lihong V. Wang, Jisha V Somasekharan, Mikell Paige
Publikováno v:
ACS Nano
One of the primary challenges in breast cancer diagnosis and treatment is intratumor heterogeneity (ITH), i.e., the co-existence of different genetically and epigenetically distinct malignant cells within the same tumor. Thus, the identification of I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31b47776e7090f0f1ec22b6422bd61ca
https://pubmed.ncbi.nlm.nih.gov/33464827
https://pubmed.ncbi.nlm.nih.gov/33464827
Publikováno v:
Breast Care (Basel)
Introduction: Trastuzumab deruxtecan is a monoclonal antibody linked to a chemotherapy moiety that was recently approved by the Food and Drug Administration (FDA) for the treatment of metastatic human epidermal growth factor receptor 2 (HER2) positiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e4eb74370a7b24d900eedc2049e22bd
https://europepmc.org/articles/PMC8436604/
https://europepmc.org/articles/PMC8436604/
Autor:
Aditya Bardia, Patrick Neven, Guillermo Streich, Alberto J. Montero, Frédéric Forget, Marie-Ange Mouret-Reynier, Joo Hyuk Sohn, Peter Vuylsteke, Kathleen K. Harnden, Hung Khong, Judit Kocsis, Florence Dalenc, Virginia Kaklamani, Patrick Dillon, Sunil Babu, Simon Waters, Ines Deleu, José García-Sáenz, Emilio Bria, Marina Cazzaniga, Janice Lu, Philippe Aftimos, Javier Cortes, Shubin Liu, Dirk Laurent, Maureen G. Conlan, Francois-Clement Bidard
Publikováno v:
Cancer Research. 82:GS2-02
Background: Endocrine therapy(ET) plus CDK4/6 inhibitor (i) is the mainstay for the management of estrogenreceptor-positive (ER+)/HER2- mBC. However, most patients (pts) with ER+ mBCeventually experience disease progression, including development of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::50cce204a5aa65a699dbe547a7aae994
https://doi.org/10.1158/1538-7445.sabcs21-gs2-02
https://doi.org/10.1158/1538-7445.sabcs21-gs2-02
Autor:
Muralidhar Beeram, Erika Hamilton, Philippe Aftimos, Xuejing Aimee Wang, Meena Okera, Sung-Bae Kim, Peter A. Kaufman, Kalyan Banda, Tarek Meniawy, Joohyuk Sohn, Sarah Sammons, Cynthia X. Ma, Suzanne R.L. Young, Rinath Jeselsohn, J. Thaddeus Beck, Kathleen K. Harnden, Komal Jhaveri, Cristina Saura, Kan Yonemori, Elgene Lim
Publikováno v:
Journal of Clinical Oncology. 39:1050-1050
1050 Background: Novel degraders and antagonists of ER are under evaluation in aBC, to overcome both ER mediated resistance and the bioavailability and dosing limitations of fulvestrant, the only approved SERD. ER is also overexpressed in ̃80% of EE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9a9341ea6d19ca46f1f9a7a6038bdf1a
https://doi.org/10.1200/jco.2021.39.15_suppl.1050
https://doi.org/10.1200/jco.2021.39.15_suppl.1050
Publikováno v:
Journal of Clinical Oncology. 39:e18687-e18687
e18687 Background: The long-acting injectable G-CSF, pegfilgrastim and its biosimilars have historically been given to patients 24 hours following the administration of myelosuppressive chemotherapy for either primary or secondary prophylaxis of febr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::38a0c516a2d394575c837b0d3d7b9135
https://doi.org/10.1200/jco.2021.39.15_suppl.e18687
https://doi.org/10.1200/jco.2021.39.15_suppl.e18687
Publikováno v:
Pediatrics. 137
There is growing interest in the relationship between dietary habits and cancer. Dietary fibers are a complex group of oligosaccharides, polysaccharides, resistant starch, and resistant dextrins. There is longstanding evidence that dietary fibers may
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::98954b6ef8097b206fd2b42de1368663
https://doi.org/10.1542/peds.2015-4376
https://doi.org/10.1542/peds.2015-4376
Publikováno v:
BMC Medicine
Next generation sequencing (NGS) coupled with sophisticated bioinformatics tools yields an unprecedented amount of information regarding tumor genetics, with the potential to reveal insights into tumor behavior. NGS and other multiplex genomic assays
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::282894e703c4b2f12962b672458d4dff
https://pubmed.ncbi.nlm.nih.gov/25286031
https://pubmed.ncbi.nlm.nih.gov/25286031
Autor:
Kathleen K. Harnden, Kouros Owzar, Kimberly L. Blackwell, Jeffrey Peppercorn, P. Kelly Marcom, H. Kim Lyerly, Michael A. Morse, Gretchen Kimmick, Amy Hobeika, Erika Hamilton
Publikováno v:
Clinical Communications-Oncology. 2:1
Introduction: Zoledronic acid (ZA) in combination with endocrine therapy (ET) and ovarian ablation yielded a disease-free survival and overall survival advantage in women with estrogen receptor+ early stage breast cancer (EBC). Evidence from preclini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::08deab49b371fd59437504aab387d56e
https://doi.org/10.4103/2393-8633.153998
https://doi.org/10.4103/2393-8633.153998